The Objective of the Present Study Is to Analyze National and International Pharmacovigilance
Data For Potential Signals In the Pharmacovigilance Data Analysis. Vigiflow Software Was Used to Assess
Causality, Seriousness, Severity of Spontaneous Adverse Drug Reaction Reportage Formulas As Described
In the National Pharmacovigilance Program and to Enter the Who Database. Who Experts Evaluated
These Data and Certification Was Made By Who For the Entry of Data In Vigiflow. In Relation to Important
Information, Which Led to Difficulties Carrying Out the Causality Assessment, the Adr Forms Reported
Under the National Pharmacovigilance Program Were Not Complete. This Is Not Only Because Healthcare
Professionals Know About the Importance of Adr Reporting, But Also Because There Are No Columns In
The Adr Form Itself That Provide some Important Facts Necessary to Evaluate Causality.
Pharmacovigilance In India Hasn't Been Very Advanced. This May Be Because the Health Workers Are
Ignorant and the Drug Safety Surveillance Is Not Properly Trained. the Facts Generated In Other Countries,
Advisory Notes Issued and Regulatory Measures Taken By Regulators Elsewhere Depend Heavily on India.
However, If Circumstances Differ, Information Obtained In One Country May Not Be Relevant to any Other
Part of the World. This Requires Us to Produce Indigenous Data That Would Be More Significant and Have
An Educational Value and Could Contribute to National Decision-Making on Regulatory Matters. It Is